A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis.

Chao HouZhuang-Zhuang JiangBo PanXiao-Chun Zhang Yan-Qing Liu

Published in: Evidence-based complementary and alternative medicine : eCAM (2021)

The combination treatment of apatinib plus chemotherapy provides better clinical benefits for OC patients when compared to chemotherapy alone and should be recommended for suitable patients with OC after the failure of standard regimens. However, further investigation into future large-scale prospective randomized research is still needed.

Keyphrases

locally advanced
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
open label
peritoneal dialysis
prognostic factors
squamous cell carcinoma
chemotherapy induced
current status